Pricing Log in Create free account

Adaptimmune Therapeutics PLC (ADAPY) vs Dare Bioscience, Inc. (DARE)

Adaptimmune Therapeutics PLC and Dare Bioscience, Inc. are both Biotechnology companies. Adaptimmune Therapeutics PLC and Dare Bioscience, Inc. are of similar size ($14.6M and $14.6M). Dare Bioscience, Inc. grew revenue faster over the last twelve months: 7,817.5% against −54.0%. Adaptimmune Therapeutics PLC has the higher net margin (−262.5% vs −804.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Adaptimmune Therapeutics PLC leads on 11 and Dare Bioscience, Inc. on 5.

Valuation

Metric ADAPY DARE Biotechnology median
P/E n/m n/m 8.50
P/S 0.12 7.85 9.71
P/B n/m n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 0.12 4.73 9.21
Earnings yield (2,166.67%) (97.22%) (33.15%)
Free cash flow yield (2,380.45%) (108.22%) (25.50%)

Profitability

Metric ADAPY DARE Biotechnology median
Gross margin 94.81% 58.84% 65.16%
Operating margin (427.75%) (813.35%) 0.00%
Net margin (262.46%) (804.33%) 0.00%
Free cash flow margin (288.20%) (849.36%) 0.00%
Return on equity (1,349.52%) 165.29% (56.36%)
Return on assets 0.00% (62.16%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ADAPY DARE Biotechnology median
Revenue growth (TTM) (53.99%) 7,817.51% 6.02%
EPS growth (last fiscal year) 142.86% (150.00%) 30.26%
Revenue growth, 5-year CAGR 8.40% 66.71% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ADAPY DARE Biotechnology median
Debt to equity (0.36) 0.00 0.00
Current ratio 1.52 0.99 4.72
Net debt to EBITDA 0.47 2.07 0.96

Dividend

Metric ADAPY DARE Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ADAPY DARE Biotechnology median
Market cap 14.55m 14.56m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack